Mastocytosis: update on pharmacotherapy and future directions
Open accessThe DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Abstract
INTRODUCTION: Mastocytosis is a disorder characterized by abnormal mast cell (MC) accumulation in skin and internal organs such as bone marrow. The disease follows a benign course in most patients with cutaneous and indolent systemic mastocytosis (SM); however, advanced variants associated with decreased life expectancy also exist. Pharmacotherapy of mastocytosis is aimed at the control of symptoms caused by MC mediator release, treatment of comorbidities and cytoreductive therapies in advanced variants. AREAS COVERED: This article will cover the general treatment principles of anti-MC mediator and cytoreductive therapies of mastocytosis. The literature discussed was retrieved with PubMed using the search terms 'treatment of mastocytosis,' 'mastocytosis antimediator therapy' and looking for important cross-references. EXPERT OPINION: Pharmacotherapy of mastocytosis should be individualized for each patient considering the category of disease, reduction of risk of anaphylaxis, constitutional symptoms and comorbidities including osteoporosis. Cytoreductive therapies are generally reserved for patients with aggressive mastocytosis (ASM), MC leukemia (MCL) and MC sarcoma (MCS); however, some patients with indolent disease and recurrent anaphylactic episodes not responsive to antimediator therapies may also be considered for cytoreduction on a case-by-case basis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Valent, P., Akin, C., Escribano, L., Födinger, M., Hartmann, K., Brockow, K., Castells, M., Sperr, W. R., Kluin‐Nelemans, H. C., Hamdy, N. A. T., et al. (2007) · European Journal of Clinical Investigation · doi:10.1111/j.1365-2362.2007.01807.x · Cited by 750 · cited 3×
“The World Health Organization (WHO) classification of mastocytosis includes 7 categories (Table 1) [1,2].”
BackgroundSelf-citationValent, P., Akin, C., Arock, M., Brockow, K., Butterfield, J. H., Carter, M. C., Castells, M., Escribano, L., Hartmann, K., Lieberman, P., et al. (2012) · International Archives of Allergy and Immunology · doi:10.1159/000328760 · Cited by 654
Self-citationIncreased production of prostaglandin D2 in patients with systemic mastocytosis
Roberts, L. J., Sweetman, B. J., Lewis, R. A., Austen, K. F., & Oates, J. A. (1980) · New England Journal of Medicine · doi:10.1056/nejm198012113032405 · Cited by 423
Masitinib (AB1010), a potent and selective tyrosine kinase inhibitor targeting KIT
Dubreuil, P., Letard, S., Ciufolini, M., Gros, L., Humbert, M., Castéran, N., Borge, L., Hajem, B., Lermet, A., Sippl, W., et al. (2009) · PLoS ONE · doi:10.1371/journal.pone.0007258 · Cited by 421 · cited 1×
“Masitinib (AB1010) is a KIT inhibitor that has initially been used in veterinary medicine to treat MC tumors in canines and has subsequently shown in vitro activity against WT KIT in human MCs, PDGFR and Lyn [102,103].”
BackgroundBonadonna, P., Perbellini, O., Passalacqua, G., Caruso, B., Colarossi, S., Dal Fior, D., Castellani, L., Bonetto, C., Frattini, F., Dama, A., et al. (2009) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2008.11.018 · Cited by 392
Oude Elberink, J. N. G., de Monchy, J. G. R., Kors, J. W., van Doormaal, J. J., & Dubois, A. E. J. (1997) · Journal of Allergy and Clinical Immunology · doi:10.1016/s0091-6749(97)81058-5 · Cited by 203
Omalizumab for the treatment of unprovoked anaphylaxis in patients with systemic mastocytosis
Carter, M. C., Robyn, J. A., Bressler, P. B., Walker, J. C., Shapiro, G. G., & Metcalfe, D. D. (2007) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2007.03.032 · Cited by 172 · cited 1×
“9 Omalizumab A few case series and reports have suggested anti-IgE therapy as being of potential value to the treatment of mastocytosis, particularly in the context of recurrent anaphylaxis [75,76].”
BackgroundMast cell mediators in allergic inflammation and mastocytosis
Castells, M. (2006) · Immunology and Allergy Clinics of North America · doi:10.1016/j.iac.2006.05.005 · Cited by 112 · cited 1×
“Antagonizing the effects of cysLTs is intuitively a sound approach considering that MCs release ample amounts of these mediators [48], and that higher levels of the end metabolite of cysLTs, LTE4, may be found in the urine of patients with SM [49].”
BackgroundButterfield, J. H., & Weiler, C. R. (2008) · International Archives of Allergy and Immunology · doi:10.1159/000144042 · Cited by 81
Leukotriene-receptor inhibition for the treatment of systemic mastocytosis
Tolar, J., Tope, W. D., & Neglia, J. P. (2004) · New England Journal of Medicine · doi:10.1056/nejm200402123500723 · Cited by 70 · cited 1×
“Two case reports have pointed out the clinical utility of LTRAs, one in an infant with bullous cutaneous mastocytosis with prominent wheezing, the other in a girl with UP, highly elevated serum tryptase levels and systemic symptoms including flushing, diarrhea, abdominal pain and urinary incontinence, both cases refra…”
Background
Cited by
Weiler, C. R., Austen, K. F., Akin, C., Barkoff, M. S., Bernstein, J. A., Bonadonna, P., Butterfield, J. H., Carter, M., Fox, C. C., Maitland, A., et al. (2019) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2019.08.023 · Cited by 123
Systemic Mastocytosis, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology
Gotlib, J., Gerds, A. T., Bose, P., Castells, M. C., Deininger, M. W., Gojo, I., Gundabolu, K., Hobbs, G., Jamieson, C., McMahon, B., et al. (2018) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2018.0088 · Cited by 106
Gülen, T., Akin, C., Bonadonna, P., Siebenhaar, F., Broesby-Olsen, S., Brockow, K., Niedoszytko, M., Nedoszytko, B., Oude Elberink, H. N. G., Butterfield, J. H., et al. (2021) · The Journal of Allergy and Clinical Immunology: In Practice · doi:10.1016/j.jaip.2021.06.011 · Cited by 83
“Optimally, the therapy should target the elevated mediators and control symptoms at the lowest effective dose.(77-80) When available, measurement of the urinary mediators (both at baseline and during the flares) is worthwhile because it enables the specific mediator(s) causing the symptoms to be targeted.”
BackgroundSelf-citationAvapritinib versus placebo in indolent systemic mastocytosis
Gotlib, J., Castells, M., Elberink, H. O., Siebenhaar, F., Hartmann, K., Broesby-Olsen, S., George, T. I., Panse, J., Alvarez-Twose, I., Radia, D. H., et al. (2023) · NEJM Evidence · doi:10.1056/evidoa2200339 · Cited by 81
Self-citationMast cell activation disorders
Akin, C. (2014) · The Journal of Allergy and Clinical Immunology: In Practice · doi:10.1016/j.jaip.2014.03.007 · Cited by 56
“TREATMENT All patients with systemic mast cell activation or a history of anaphylaxis should be prescribed multiple self-injectable epinephrine devices and be trained in their appropriate use.(45) Those who are allergic to Hymenoptera venom should be recommended VIT.”
BackgroundSelf-citation
Metadata
- Authors
- Cardet, J. C., Akin, C., & Lee, M. J.
- Venue
- Expert Opinion on Pharmacotherapy
- Publisher
- Informa UK Limited
- Published
- 2013-09-17
- Volume
- 14
- Issue
- 15
- Pages
- 2033-2045
- ISSN
- 1465-6566 (ISSN-L)
- 1744-7666
- OpenAlex
- W2156972368
- Cited by
- 49
- References
- 12
- FWCI
- 2.20
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Mastocytosis: update on pharmacotherapy and future directions. https://app.cochat.ai/papers/10.1517/14656566.2013.824424
- The paper
- Cardet, J. C., Akin, C., & Lee, M. J. (2013). Mastocytosis: update on pharmacotherapy and future directions. Expert Opinion on Pharmacotherapy. https://doi.org/10.1517/14656566.2013.824424
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.